Historically Discounted RTI Surgical Transitioning To Pure Play Spine Competitor With Significant Upside

RTI Surgical (RTIX, now SRGA) is on the precipice of a transformation due to the divestiture of its OEM business to Montagu Private Equity. This divestiture can be viewed as the culmination of several years’ work to simplify the business by its relatively new CEO, Camille Farhat, as well as the beginning of an exciting transition to a pure-play high margin growing spine company and hopefully, the accompanying valuation. At 1035 Capital, we have followed SRGA since Farhat was hired as CEO and waited for this kind of catalyst to make SRGA a really exciting opportunity. Read more on Seeking…
Read More

OptimizeRx Corp: Optimize Your Portfolio With This Under The Radar Health Tech Company

OptimizeRx Corporation (OPRX) is a healthcare IT company focused on improving messaging between manufacturers, patients, payors and doctors. OPRX's first major product, financial messaging, allowed it to penetrate the healthcare communications space. Since then, the company has added 3 additional products which are moving OPRX up the value chain toward enterprise deals where it will provide a variety of messaging solutions instead of one-off project work. Read more on Seeking Alpha...
Read More

Teligent: 100% Upside Based On Revised SOTP With Several Near-Term Catalysts

1035 Capital recently wrote an article on TLGT highlighting the underappreciated value of this turnaround generic manufacturer. As we predicted, there has been significant volatility in the share price. Since publication on Aug 8th, the price spiked up to ~$1.10 and has recently slid all the way back to the $0.60 range. In our previous article, 1035 Capital provided background information on TLGT and we argued the company is worth $2-2.75/share. Recent announcements within the past month have provided us a better understanding of the value of the company’s assets and based on this new information, we believe the sum of TLGT’s…
Read More

Supernus Pharmaceuticals: Anti-CGRPs Are Causing Migraines For This Biotech But Investors Are Too Pessimistic Creating A Compelling Opportunity

Supernus Pharmaceuticals (SUPN) was founded in 2005 and was previously a subsidiary of Shire PLC (SHPG). SUPN and its management team have developed and commercialized the central nervous system ("CNS") products for more than 25 years. The company's two commercial products are Oxtellar XR® and Trokendi XR® both originally for the treatment of epilepsy. SUPN drugs are extended-release versions of earlier immediate-release branded products. SUPN found that by using extended-release formulations, these two molecules could achieve smoother blood saturation levels resulting in patients with fewer negative side effects and better disease management. In August 2016, SUPN expanded the label for Trokendi by gaining…
Read More

Teligent: Micro-Cap Specialty Generic

Teligent (NASDAQ: TLGT) currently produces over 70 topical and injectable products across the US and Canada. TLGT was once an exciting high growth generic manufacturer but stumbled in the last few years as they invested to expand their manufacturing capabilities. The company embarked on a strategy to focus on TICO, topical, injectable, complex and ophthalmic generics in 2014 under the premise that there are less competition and greater pricing stability in these niche portions of the generic market. Given the small size of TLGT, these niche markets still provide plenty of room for growth. While the strategy to shift the…
Read More